Essential medicines for cancer: WHO recommendations and national priorities

被引:83
|
作者
Robertson, Jane [1 ]
Barr, Ronald [2 ]
Shulman, Lawrence N. [3 ]
Forte, Gilles B.
Magrini, Nicola [4 ]
机构
[1] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW, Australia
[2] McMaster Univ, Dept Pediat Pathol & Med, Hamilton, ON, Canada
[3] Univ Penn, Ctr Global Canc Med, Philadelphia, PA 19104 USA
[4] World Hlth Org, Dept Essential Med & Hlth Prod, 20 Ave Appla, CH-1211 Geneva 27, Switzerland
关键词
CLINICAL ONCOLOGY; AMERICAN SOCIETY; MIDDLE; SELECTION; CHILDREN; BENEFIT; PRICE; COST; CARE;
D O I
10.2471/BLT.15.163998
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective To examine, for essential anti-cancer medicines, the alignment of national lists of essential medicines and national reimbursable medicines lists with the World Health Organization's (WHO's) Model Lists. Methods National medicine lists for 135 countries with per-capita gross national incomes below 25 000 United States dollars in 2015 were compared with WHO's 2013 and 2015 Model Lists of Essential Medicines. Correlations between numbers of anti-cancer medicines included in national lists and gross national income (GNI), government health expenditure and number of physicians per 1000 population were evaluated. Findings Of the 25 anti-cancer medicines on the 2013 Model List and the 16 added via the 2015 revision of the Model List, 0-25 (median: 17) and 0-15 (median: 3) appeared in national lists, respectively. There was considerable variability in these numbers within and between World Bank income groups. Of the 16 new medicines included in the 2015 Model List, for example, 0-10 (median: 1) and 2-15 (median: 10) were included in the national lists of low-income and high-income countries, respectively. The numbers of these new medicines included in national lists were significantly correlated (P <= 0.0001) with per-capita GNI (r=0.45), per-capita annual government health expenditure (r= 0.33) and number of physicians per 1000 population (r=0.48). Twenty-one countries (16%) included the targeted anti-cancer medicines imatinib, rituximab and trastuzumab in their national lists. Conclusion Substantial numbers of anti-cancer medicines are included in national lists of low- and middle-income countries but the availability, affordability, accessibility and administration feasibility, of these medicines, at country-level, need assessment.
引用
收藏
页码:735 / 742
页数:8
相关论文
共 50 条
  • [21] Medicines for cancers in children: The WHO model for selection of essential medicines
    Robertson, Jane
    Magrini, Nicola
    Barr, Ronald
    Forte, Gilles
    Ondari, Clive
    PEDIATRIC BLOOD & CANCER, 2015, 62 (10) : 1689 - 1693
  • [22] Monographs for medicines on WHO's Model List of Essential Medicines
    Roth, Lukas
    Adler, Melissa
    Jain, Tanvi
    Bempong, Daniel
    BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2018, 96 (06) : 378 - 385
  • [23] Access to essential medicines in national constitutions
    Perehudoff, S. K.
    Laing, R. O.
    Hogerzeil, H. V.
    BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2010, 88 (11) : 800 - 800
  • [24] Global status of essential medicine selection: a systematic comparison of national essential medicine lists with recommendations by WHO
    Piggott, Thomas
    Nowak, Artur
    Brignardello-Petersen, Romina
    Cooke, Graham S.
    Huttner, Benedikt
    Schunemann, Holger J.
    Persaud, Nav
    Magrini, Nicola
    Moja, Lorenzo
    BMJ OPEN, 2022, 12 (02):
  • [25] Access and use of WHO essential medicines in Italy
    Petrella, Alessandro
    Fortinguerra, Filomena
    Cangini, Agnese
    Pierantozzi, Andrea
    Trotta, Francesco
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [26] Appropriate use of essential medicines in the elderly: a comparison of the WHO essential medicines list and PIM criteria
    Xin Ma
    Xuxu Yin
    Meng Li
    Yanwen Wang
    Hongxia Xin
    Wei Liu
    European Journal of Clinical Pharmacology, 2021, 77 : 509 - 516
  • [27] Diabetes and the WHO Model List of Essential Medicines
    Danne, Thomas
    Ampudia-Blasco, Francisco Javier
    Mathieu, Chantal
    LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (01): : 18 - 19
  • [28] Appropriate use of essential medicines in the elderly: a comparison of the WHO essential medicines list and PIM criteria
    Ma, Xin
    Yin, Xuxu
    Li, Meng
    Wang, Yanwen
    Xin, Hongxia
    Liu, Wei
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (04) : 509 - 516
  • [29] Insights from the WHO and National Lists of Essential Medicines: Focus on Pediatric Diabetes Care in Africa
    Rowlands, Amanda
    Ameyaw, Emmanuel
    Rutagarama, Florent
    Dipesalema, Joel
    Majaliwa, Edna Siima
    Mbogo, Joyce
    Ogle, Graham D.
    Chanoine, Jean-Pierre
    HORMONE RESEARCH IN PAEDIATRICS, 2018, 90 (02): : 82 - 92
  • [30] Adaptation of the WHO Essential Medicines List for national antibiotic stewardship policy in England: being AWaRe
    Budd, Emma
    Cramp, Emma
    Sharland, Mike
    Hand, Kieran
    Howard, Philip
    Wilson, Peter
    Wilcox, Mark
    Muller-Pebody, Berit
    Hopkins, Susan
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (11) : 3384 - 3389